$220 Million is the total value of Stonepine Capital Management, LLC's 31 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 36.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CBIO | Sell | CATALYST BIOSCIENCES INC | $10,830,000 | -18.7% | 2,635,014 | -14.3% | 4.93% | -29.3% |
| CDTX | Sell | CIDARA THERAPEUTICS INC | $1,754,000 | -28.3% | 782,817 | -35.4% | 0.80% | -37.7% |
| XOMA | Sell | XOMA CORP | $1,696,000 | -69.8% | 68,542 | -58.5% | 0.77% | -73.7% |
| EYPT | Sell | EYEPOINT PHARMACEUTICALS INC | $839,000 | -69.3% | 80,537 | -73.5% | 0.38% | -73.3% |
| DMAC | Sell | DIAMEDICA THERAPEUTICS INC | $665,000 | -64.4% | 165,775 | -60.5% | 0.30% | -69.0% |
| CFMS | Sell | CONFORMIS INC | $648,000 | -91.5% | 486,982 | -92.7% | 0.30% | -92.6% |
| CFRX | Sell | CONTRAFECT CORP | $139,000 | -53.0% | 34,413 | -48.8% | 0.06% | -59.4% |
| AGTC | Exit | APPLIED GENETIC TECHNOLOGIES | $0 | – | -1,000 | -100.0% | -0.00% | – |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -46,886 | -100.0% | -0.06% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -517,445 | -100.0% | -1.71% | – |
| CHMA | Exit | CHIASMA INC | $0 | – | -6,770,000 | -100.0% | -16.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.